Abstract:Background: Acute lung injury (ALI) is a severe inflammatory disorder associated with high morbidity and mortality rates. Various therapeutic strategies for ALI have been proposed over the last few decades; however, the treatment options remain limited. Mai-Luo-Ning injection (MLN), a traditional Chinese medical formulation, has been extensively used for the treatment of respiratory diseases. Nevertheless, the effects of MLN on ALI remain unclear. Purpose: This study aimed to investigate the protective and therapeutic effects of MLN on lipopolysaccharide-induced ALI mouse models and RAW 264.7 cells, and further explore the underlying mechanism of these effects. Methods: The therapeutic activity of MLN was evaluated using an in vivo ALI model and an in vitro model of RAW 264.7 macrophages. UHPLC-ESI-Q-TOF-MS/MS was used to investigate the chemical constituents of the MLN. The material basis and potential protective mechanism of MLN were analyzed using network pharmacology. The roles of MLN in inhibiting the Toll-like receptor 4 (TLR4)/ nuclear factor kappa B (NF-κB) signalling pathway were investigated via western blotting, real-time polymerase chain reaction, enzyme-linked immunosorbent assay, and immunofluorescence staining. Results: In vivo experiments demonstrated that MLN ameliorated LPS-induced histological changes in lung tissues and reduced lung wet/dry weight ratio, total protein concentration in the bronchoalveolar lavage fluid and myeloperoxidase activity. Furthermore, MLN downregulated the in vivo and in vitro expression of pro-inflammatory cytokines such as tumour necrosis factor-alpha, interleukin-6, and interleukin-1β. Network pharmacology analysis revealed that MLN could act synergistically through multiple targets and pathways and exert a protective effect, possibly through inhibiting TLR4/ NF-κB signalling pathways. Western blotting and immunofluorescence experiments further confirmed that MLN could regulate the expression of TLR4, MyD88, phospho-IκB-α, and phospho-NF-κB p65 in the TLR4/NF-κB signalling pathway and decrease the translocation of phospho-NF-κB p65 into the nucleus. Conclusion: This study suggests that MLN has a potential protective effect against LPS-induced ALI, which might be associated with the inhibition of the TLR4/NF-κB signalling pathway. Therefore, MLN is worthy of further investigation as a potential candidate for the treatment of ALI in the future.

Natural Molecule Munronoid I Attenuates LPS-induced Acute Lung Injury by Promoting the K48-linked Ubiquitination and Degradation of TAK1.

Monoammonium Glycyrrhizinate Inhibited The Inflammation Of Lps-Induced Acute Lung Injury In Mice

Standardized Myrtol Attenuates Lipopolysaccharide Induced Acute Lung Injury in Mice

Plantamajoside Ameliorates Lipopolysaccharide-Induced Acute Lung Injury Via Suppressing NF-κB and MAPK Activation.

LYRM03, an Ubenimex Derivative, Attenuates LPS- Induced Acute Lung Injury in Mice by Suppressing the TLR4 Signaling Pathway

Tabersonine Attenuates Lipopolysaccharide-Induced Acute Lung Injury Via Suppressing TRAF6 Ubiquitination.

The protective effects of Mai-Luo-Ning injection against LPS-induced acute lung injury via the TLR4/NF-κB signalling pathway

Tetramethylpyrazine ameliorates LPS-induced acute lung injury via the miR-369-3p/DSTN axis

Ursolic acid attenuates lipopolysaccharide-induced acute lung injury in a mouse model.

Diterpene Coronarin Attenuates Lipopolysaccharide-Induced Acute Lung Injury in Both In Vivo and In Vitro Models

Synergistic Protection of Matrine and Lycopene Against Lipopolysaccharide‑induced Acute Lung Injury in Mice.

Protostemonine Effectively Attenuates Lipopolysaccharide-Induced Acute Lung Injury in Mice

Emodin Protects Against Lipopolysaccharide-Induced Acute Lung Injury via the JNK/Nur77/c-Jun Signaling Pathway

Emodin Protects Against Lipopolysaccharide-Induced Acute Lung Injury <i>via</i> the JNK/Nur77/c-Jun Signaling Pathway

Mechanism of MCP-1 in Acute Lung Injury and Advanced Therapy by Drug-Loaded Dextrin Nanoparticle

Danshensu methyl ester attenuated LPS-induced acute lung injury by inhibiting TLR4/NF-κB pathway

4-Indole-2-arylaminopyrimidine Identifies Lysosomal Cathepsin L Activation Critical for Acute Lung Injury

Aspirin-triggered Lipoxin A4 Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting Activation of Mitogen-Activated Protein Kinases and NF-κB in Mice.

Monotropein alleviates sepsis-elicited acute lung injury via the NF-κB pathway.

Mefunidone ameliorates lipopolysaccharide-induced acute lung injury through inhibiting MAPK signaling pathway and enhancing Nrf2 pathway

Suppression of MAPK and NF-κB Pathways by Limonene Contributes to Attenuation of Lipopolysaccharide-Induced Inflammatory Responses in Acute Lung Injury